Shots:
- Arthrosi Therapeutics has completed patient enrolment in P-III (REDUCE 1) trial of pozdeutinurad (AR882) to reduce the serum urate (sUA) levels & tophi in gout and tophaceous gout pts
- The P-III (REDUCE 1) trial assessed pozdeutinurad (50 or 75mg) vs PBO in 750 pts with a majority being inadequate responders to urate lowering therapies
- Trial will assess sUA reduction by 6mos. as 1EP while the 2EPs incl. tophi & flare reduction, with data expected by Q2’26. Comprehensive data from P-III (REDUCE 1 & 2) trials is expected in Q4’26 & will support potential NDA filing
Ref: PRNewswire | Image: Arthrosi Therapeutics|Press Release
Related News:- Akeso Reports First Patient Dosing in P-III (COMPASSION-33) Trial of Cadonilimab for G/GEJ Adenocarcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
